Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDL Diagnostics ABFRA:80R +5.79%55 Interest Coverage is 11.30 as of Mar. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates FRA:80R with a GF Score™ of 55/100 and a GF Value™ of €0.03. The stock has 2 warning signs investors should review. Among 93 Medical Diagnostics & Research companies, IDL Diagnostics AB ranks worse than 1075267.74% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. IDL Diagnostics AB's
Operating Income
for the
three
months ended in Mar. 2026 was €0.11 Mil. IDL Diagnostics AB's Interest Expense for the
three
months ended in Mar. 2026 was €-0.01 Mil.
IDL Diagnostics AB's interest coverage for the quarter that ended in Mar. 2026 was 11.30.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for IDL Diagnostics AB's Interest Coverage or its related term are showing as below:
FRA:80R's Interest Coverage is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 9.05 * Ranked among companies with meaningful Interest Coverage only.
IDL Diagnostics AB (FRA:80R) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
IDL Diagnostics AB Interest Coverage Related Terms
IDL Diagnostics AB Interest Coverage Historical Data
* Premium members only.
The historical data trend for IDL Diagnostics AB's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:80R vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, IDL Diagnostics AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDL Diagnostics AB Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDL Diagnostics AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where IDL Diagnostics AB's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDL Diagnostics AB (FRA:80R) has a Interest Coverage of 11.30 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on IDL Diagnostics AB and its competitors. This is 100% below median its historical median of 10,000.00. According to the industry distribution chart, IDL Diagnostics AB ranks #999999 out of 93 companies in the Medical Diagnostics & Research industry.
Is IDL Diagnostics AB's Interest Coverage too high?
IDL Diagnostics AB's current Interest Coverage of 11.30 is 100% below median its 10-year median of 10,000.00. The Medical Diagnostics & Research industry median Interest Coverage is 9.05. IDL Diagnostics AB's value of 11.30 is 24.9% above this industry median. Based on the distribution chart, IDL Diagnostics AB ranks #999999 out of 93 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, IDL Diagnostics AB has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does IDL Diagnostics AB's Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, IDL Diagnostics AB ranks #999999 out of 93 companies for Interest Coverage. This places IDL Diagnostics AB in the lower half of its industry. The industry median Interest Coverage is 9.05. IDL Diagnostics AB's value of 11.30 is 24.9% above this benchmark. While the company's 10-year median is 10,000.00 vs. the industry median of 9.05, IDL Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.05, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDL Diagnostics AB's current Interest Coverage of 11.30 is 24.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on IDL Diagnostics AB and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDL Diagnostics AB's current Interest Coverage is 11.30, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDL Diagnostics AB stock overvalued right now?
IDL Diagnostics AB (FRA:80R) has a current Interest Coverage of 11.30. The stock's GF Value™ is €0.03, compared to a current price of €0.03 — trading 14.7% below its estimated fair value. The current Interest Coverage is 11.30, which is 100% below median its 10-year median of 10,000.00 and 24.9% above the Medical Diagnostics & Research industry median of 9.05. IDL Diagnostics AB's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For IDL Diagnostics AB (FRA:80R), the current Interest Coverage is 11.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDL Diagnostics AB (FRA:80R) Overvalued in 2026?
Based on GuruFocus' analysis, IDL Diagnostics AB stock appears to be undervalued.
The current stock price of €0.03 is trading 14.7% below its estimated GF Value™ of €0.03.
Key valuation signals for FRA:80R:
Interest Coverage: 11.30 (100% below median its 10-year median of 10,000.00)
GF Value™: €0.03 vs. price of €0.03 (14.7% below fair value)
Industry Position: 24.9% above the Medical Diagnostics & Research median (#999999 of 93)
No single metric tells the full story. See the FRA:80R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDL Diagnostics AB is a Swedish company that develops and markets blood and urine sample tests. It specializes in oncology and bacteriology. The company has a broad product portfolio, is used in healthcare, and is established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1 and cytokeratins, to support the treatment of cancers such as breast, prostate, and bladder cancers.
55GF Score
Get the complete analysis for FRA:80R
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:80R has been successfully added to your 
